Emerging Companies

April 17, 2013

The fifth annual edition of Scientific American Worldview explores ongoing challenges and...

April 15, 2013

Rob Wright, chief editor of Life...

February 25, 2013

Recently BIO hosted the 15th annual BIO CEO & Investor Conference at the Waldorf Astoria...

February 12, 2013

From the 15th Annual BIO CEO & Investor Conference at the Waldorf Astoria Hotel in New...

Letters, Testimony & Comments

July 26 2012
Jeffrey S. Hatfield, President and Chief Executive Officer of Vitae Pharmaceuticals, testified on behalf of BIO about the 10th anniversary of the Sarbanes-Oxley Act.
March 16 2012
On behalf of BIO and its more than 1,100 members, Jim Greenwood submitted a letter to Senate Majority Leader Harry Reid and Minority Leader Mitch McConnell in strong support of H.R. 3606, the Jumpstart Our Business Startups (JOBS) Act.
March 6 2012
William D. Waddill, Senior Vice President and Chief Financial Officer of OncoMed Pharmaceuticals highlights the importance of capital formation to encourage investment in the biotechnology industry and spur job growth across the country.
December 1 2011
On December 1, BIO submitted written testimony to the Senate Committee on Banking, Housing, and Urban Affairs on the importance of implementing policies that will spur job growth through capital formation while protecting investors.  
May 25 2011
Representatives of the bioscience industry testified before the U.S. Congress Joint Economic Committee today, as part of a hearing entitled Driving Innovation and Job Growth through the Life Sciences Industry.

Press Releases

May 21 2013
CSBI encourages a tax code that promotes economic growth and creates jobs.
May 16 2013
H.R. 701 sets a deadline to complete rule-making on Regulation A reforms.
May 15 2013
H.R. 1952 will stimulate trading for small public companies.
January 8 2013
Small Business Innovation Research grants provide critical support for emerging biotech companies working on cures and treatments.
September 25 2012
Bill would stimulate capital formation for small biotech companies.